Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3735-9. doi: 10.1016/j.bmcl.2006.04.045. Epub 2006 May 15.

Abstract

Systematic modification of a screening lead yielded a class of potent glycinamide based CCR2 antagonists. The best compound (55, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-{[2-(1-piperidinyl)ethyl]amino}-2-(3-thienyl)acetamide) displayed good binding affinity (IC50=30 and 39 nM) toward human monocytes and CHO cell expressing human CCR2b, respectively. Functionally, it blocked MCP-1 (CCL2)-induced calcium mobilization (IC50=50 nM) and chemotaxis mediated through the CCR2 receptor (9.6 nM). It is selective against other chemokine receptors tested.

MeSH terms

  • Animals
  • Binding Sites
  • CHO Cells / drug effects
  • Calcium / metabolism
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / metabolism
  • Cricetinae
  • Glycine / analogs & derivatives*
  • Glycine / chemical synthesis
  • Glycine / chemistry
  • Glycine / pharmacology
  • Humans
  • Inhibitory Concentration 50
  • Models, Biological
  • Monocytes / drug effects*
  • Receptors, CCR2
  • Receptors, Chemokine / antagonists & inhibitors*
  • Receptors, Chemokine / metabolism

Substances

  • CCL2 protein, human
  • CCR2 protein, human
  • Chemokine CCL2
  • Receptors, CCR2
  • Receptors, Chemokine
  • glycine amide
  • Calcium
  • Glycine